Newsletter Summer 2009

Since 1998, Protéus develops and delivers high-performance proteins and protein-based processes for industry, in particular for the healthcare, chemistry, bioenergy and environmental sectors. 

Protéus newsletter today highlights our activity in the healthcare sector. 

Proteus has created two dedicated specific structures to serve the needs of pharmaceutical and biotech industry:
- “Proteus Services for Industry” (PSI) provides a full range of protein-related services
- “PCAS Biosolution” manufactures and delivers intermediates and APIs 

“Our goal is to deliver improved time and cost performance” says Cécile Persillon, PhD, who leads the PSI scientific team at Protéus. This growing business of the company benefits from more than a decade of experience in protein engineering and expression. “We serve clients involved in R&D and process development in the pharma and biotech industry” she adds.

Typically, clients come to the company for the purpose of accelerating pharmaceutical R&D programs that involve e.g. investigations of protein biomarkers, high throughput screening programs based on protein binding assays, production of antigens or optimisation of antibody fragments. Actually, scientists in the pharma and biotech industry need proteins and protein-related information throughout their entire R&D process. “What we have created here is a platform that helps them to stay focused on their core business and save time and cash when it comes for instance about producing mg or grams of difficult-to-express proteins” Dr. Persillon emphasises.

Through the full spectrum of PSI services, Protéus provides effective solutions for protein production, optimisation and immunogenicity assessment:

Prod'line : The design of efficient expression systems and scaleable bioprocesses for producing the proteins needed throughout your R&D process.
Dream'line : Protein engineering based on the most efficient technologies to generate optimised lead proteins
Immuno'line : The preclinical immunogenicity evaluation and management risk immunogenicity associated to biological drugs (monoclonal antibodies, peptides, therapeutic proteins)

For more information.

To better serve its pharma and biotech clients, Protéus created a comprehensive industrial platform integrating advanced biocatalysis with up-to-date industrial chemical technologies and capabilities. 

For that purpose, Proteus teamed up with European chemical group PCAS. A major player in the industry, PCAS operates four cGMP audited multiscale chemical plants and several ISO certified sites for cost-effective back-integration of non-regulated compounds. Both companies formed PCAS Biosolution as a joint-venture dedicated to the pharmaceutical market. 

“We are committed to be the quality partner of the industry for the long term supply of intermediates and APIs using optimal chemo-biocatalytic routes that meet the most stringent specifications of quantity, time, quality and targeted price” said Jean-Marie Sonet, general manager at PCAS Biosolution.

Within less than two years, PCAS Biosolution developed three multi-step innovative processes to industrial pilot scale. Most recently, a range of enantiopure beta-chiral alcohols, aldehydes and other enantiopure derivatives was released. 

For more information, please contact :
jmsonet@pcas-bio.com 

Biotechmar

Concarneau, France 
3 sept. 2009
MNHN (Marinarium)
Round table on Marine Biotechnology.  
Overview of international players in marine biotechnology and technological issues.
The valorization chain of marine co-products for high-value molecules
Website
    

Immunogenicity
for Biologics

Prague, Czech Republic 
7 - 10 sept. 2009
Andel's Hotel
Prediction, characterisation and detection of immunogenicity of therapeutic biologics
Invited speaker : Dr Bernard Maillère, immunogenicity expert at Protéus, who will have a talk on the relevance of T-Cell based assays for immunogenicity assessment of biologics.
Website

Symbiosis

14 th European Congress on Biotechnology
Barcelona, Spain
13 -16 Sept. 2009
Analyzing the impact of life science industry in humanity's great challenges.
- Health & Medicine
- Industrial biotechnology
- Plant & Environmental Biotech
- System biology & technology
Website 

 

ChemOutsourcing Show

September 14-16, 2009
Ocean Place Resort - Long Branch, NJ, USA
Joe Tessier, General Manager of PCAS America, has been invited to speak in two panels of the meeting : Improving Drug Manufacturing through Controlled Enzyme Evolution (Conf. Track B) and Early Stage API Outsourcing and Vendor Management (Conf. Track A). 
Contact PCAS Biosolution to arrange a meeting.
Chemoutsourcing Website 

 

Eurobio 2009

Lille, France, 23 - 25 Sept. 2009
The partnering and tech transfer event for the Bioindustry
Jean-François Bloch (Deputy General Manager at Protéus) has been invited to participate to a round table “Establish win-win models with your service suppliers: outsourcing deals” .
Website
.

Biotechnica & PEGS 09

Hannovre, Germany, 6 - 8 oct. 2009
Biotechnica is one of the most important exhibition of materials and services for Life Science Industry. This year, Biotechnica is combinated with PEGS Europe (Protein Engineering Summit) 
Come and Meet Protéus on the French Pavillion
Website